Analyst picks & changes
Analysts covering Biogen Inc. and Chiron Corp. spent much of the past week digesting the data from the presentation of the Phase III trial of Biogen Inc.'s beta interferon (see BioCentury Extra, Oct. 11). The consensus was that the efficacy data, while not directly comparable to Berlex/Chiron Corp.'s
beta interferon, show the drugs to be roughly equivalent, implying an ultimate battle in the marketplace.
Ambiguities in the data